William Haning to Humans
This is a "connection" page, showing publications William Haning has written about Humans.
Connection Strength
0.364
-
Buffenstein I, Kiyokawa M, Haning W. Severe Hypothyroidism in a Hypomanic Patient With Sepsis. Prim Care Companion CNS Disord. 2021 Nov 24; 23(6).
Score: 0.040
-
Cape MC, Kiyokawa M, Haning WF. Astronomical Use of Nitrous Oxide Associated With Stress From the COVID-19 Pandemic and Lockdown. Prim Care Companion CNS Disord. 2021 09 23; 23(5).
Score: 0.040
-
Haning W. Commentary on "Civil Commitment for SUDs: A National Survey of Addiction Medicine Physicians". J Addict Med. 2021 Jul-Aug 01; 15(4):283-284.
Score: 0.039
-
Park TM, Haning WF. Stimulant Use Disorders. Child Adolesc Psychiatr Clin N Am. 2016 Jul; 25(3):461-71.
Score: 0.027
-
Nakama H, Chang L, Cloak C, Jiang C, Alicata D, Haning W. Association between psychiatric symptoms and craving in methamphetamine users. Am J Addict. 2008 Sep-Oct; 17(5):441-6.
Score: 0.016
-
Haning W, Goebert D. Electrocardiographic abnormalities in methamphetamine abusers. Addiction. 2007 Apr; 102 Suppl 1:70-5.
Score: 0.015
-
Chang L, Haning W. Insights from recent positron emission tomographic studies of drug abuse and dependence. Curr Opin Psychiatry. 2006 May; 19(3):246-52.
Score: 0.014
-
Haning WF. Comments on planning and the 3 Tesla MRI. Hawaii Med J. 2005 Apr; 64(4):104-5.
Score: 0.013
-
Juul D, Haning WF, Ronis RJ, Faulkner LR. The Development and Current Status of Subspecialty Training and Certification in Addiction Psychiatry. Acad Psychiatry. 2022 Jun; 46(3):311-316.
Score: 0.010
-
Baker FM, Haning WF. Substance abuse and dependence in a public hospital: Hawaii. Hawaii Med J. 2001 Feb; 60(2):35-8.
Score: 0.010
-
Fong SF, Sakai DH, Kasuya RT, Kramer K, Wong VS, Haning W, Asano I, Uyehara-Lock JH, Thompson K, Omori JS, Hirose-Wong SM, Horio DT. Medical School Hotline: Liaison Committee on Medical Education Accreditation, Part IV: Pre-clerkship Education. Hawaii J Med Public Health. 2016 Feb; 75(2):48-51.
Score: 0.007
-
Smith LM, Diaz S, LaGasse LL, Wouldes T, Derauf C, Newman E, Arria A, Huestis MA, Haning W, Strauss A, Della Grotta S, Dansereau LM, Neal C, Lester BM. Developmental and behavioral consequences of prenatal methamphetamine exposure: A review of the Infant Development, Environment, and Lifestyle (IDEAL) study. Neurotoxicol Teratol. 2015 Sep-Oct; 51:35-44.
Score: 0.006
-
Anderson AL, Li SH, Markova D, Holmes TH, Chiang N, Kahn R, Campbell J, Dickerson DL, Galloway GP, Haning W, Roache JD, Stock C, Elkashef AM. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2015 May 01; 150:170-4.
Score: 0.006
-
Li MD, Wang J, Niu T, Ma JZ, Seneviratne C, Ait-Daoud N, Saadvandi J, Morris R, Weiss D, Campbell J, Haning W, Mawhinney DJ, Weis D, McCann M, Stock C, Kahn R, Iturriaga E, Yu E, Elkashef A, Johnson BA. Transcriptome profiling and pathway analysis of genes expressed differentially in participants with or without a positive response to topiramate treatment for methamphetamine addiction. BMC Med Genomics. 2014 Dec 12; 7:65.
Score: 0.006
-
Kiblawi ZN, Smith LM, Diaz SD, LaGasse LL, Derauf C, Newman E, Shah R, Arria A, Huestis M, Haning W, Strauss A, DellaGrotta S, Dansereau LM, Neal C, Lester B. Prenatal methamphetamine exposure and neonatal and infant neurobehavioral outcome: results from the IDEAL study. Subst Abus. 2014; 35(1):68-73.
Score: 0.006
-
Adams D, Ditzler T, Haning WF. Primary caffeine dependence: a case report. Hawaii Med J. 1993 Jul; 52(7):190-1, 194.
Score: 0.006
-
Kirlic N, Newman E, Lagasse LL, Derauf C, Shah R, Smith LM, Arria AM, Huestis MA, Haning W, Strauss A, Dellagrotta S, Dansereau LM, Abar B, Neal CR, Lester BM. Cortisol reactivity in two-year-old children prenatally exposed to methamphetamine. J Stud Alcohol Drugs. 2013 May; 74(3):447-51.
Score: 0.006
-
Liles BD, Newman E, Lagasse LL, Derauf C, Shah R, Smith LM, Arria AM, Huestis MA, Haning W, Strauss A, Dellagrotta S, Dansereau LM, Neal C, Lester BM. Perceived child behavior problems, parenting stress, and maternal depressive symptoms among prenatal methamphetamine users. Child Psychiatry Hum Dev. 2012 Dec; 43(6):943-57.
Score: 0.005
-
Ma JZ, Johnson BA, Yu E, Weiss D, McSherry F, Saadvandi J, Iturriaga E, Ait-Daoud N, Rawson RA, Hrymoc M, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Weis D, McCann M, Pham T, Stock C, Dickinson R, Elkashef A, Li MD. Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis. Drug Alcohol Depend. 2013 Jun 01; 130(1-3):45-51.
Score: 0.005
-
Smith LM, Paz MS, LaGasse LL, Derauf C, Newman E, Shah R, Arria A, Huestis MA, Haning W, Strauss A, Della Grotta S, Dansereau LM, Neal C, Lester BM. Maternal depression and prenatal exposure to methamphetamine: neurodevelopmental findings from the infant development, environment, and lifestyle (ideal) study. Depress Anxiety. 2012 Jun; 29(6):515-22.
Score: 0.005
-
Shah R, Diaz SD, Arria A, LaGasse LL, Derauf C, Newman E, Smith LM, Huestis MA, Haning W, Strauss A, Della Grotta S, Dansereau LM, Roberts MB, Neal C, Lester BM. Prenatal methamphetamine exposure and short-term maternal and infant medical outcomes. Am J Perinatol. 2012 May; 29(5):391-400.
Score: 0.005
-
Elkashef A, Kahn R, Yu E, Iturriaga E, Li SH, Anderson A, Chiang N, Ait-Daoud N, Weiss D, McSherry F, Serpi T, Rawson R, Hrymoc M, Weis D, McCann M, Pham T, Stock C, Dickinson R, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Li MD, Johnson BA. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012 Jul; 107(7):1297-306.
Score: 0.005
-
Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, Kahn R, Chiang N, Beresford T, Campbell J, Haning W, Mawhinney J, McCann M, Rawson R, Stock C, Weis D, Yu E, Elkashef AM. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012 Jan 01; 120(1-3):135-41.
Score: 0.005
-
Zabaneh R, Smith LM, LaGasse LL, Derauf C, Newman E, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Dansereau LM, Lin H, Neal C, Lester BM. The effects of prenatal methamphetamine exposure on childhood growth patterns from birth to 3 years of age. Am J Perinatol. 2012 Mar; 29(3):203-10.
Score: 0.005
-
Derauf C, LaGasse L, Smith L, Newman E, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Dansereau L, Lin H, Lester B. Infant temperament and high-risk environment relate to behavior problems and language in toddlers. J Dev Behav Pediatr. 2011 Feb-Mar; 32(2):125-35.
Score: 0.005
-
Smith LM, LaGasse LL, Derauf C, Newman E, Shah R, Haning W, Arria A, Huestis M, Strauss A, Della Grotta S, Dansereau LM, Lin H, Lester BM. Motor and cognitive outcomes through three years of age in children exposed to prenatal methamphetamine. Neurotoxicol Teratol. 2011 Jan-Feb; 33(1):176-84.
Score: 0.005
-
Nguyen D, Smith LM, Lagasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis MA, Haning W, Strauss A, Della Grotta S, Liu J, Lester BM. Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr. 2010 Aug; 157(2):337-9.
Score: 0.005
-
Bell CK, Guerrero A, Matsu C, Takeshita J, Haning W, Schultz K. Curricular adaptations in inpatient child psychiatry for the 21st century: the Flexner model revisited. Acad Psychiatry. 2010 May-Jun; 34(3):195-202.
Score: 0.005
-
Tice AD, Bannan M, Bauman K, Collis T, Hall A, Haning W, Hannemann S, Hare CB, Humphry J, Jao R, Leevy C, Lusk H, Ochoa E, Palafox N, Withers N, Akinaka K. Viral hepatitis in Hawai'i--differing perspectives. Hawaii Med J. 2010 Apr; 69(4 Suppl 1):3-20.
Score: 0.004
-
Gray TR, Kelly T, LaGasse LL, Smith LM, Derauf C, Grant P, Shah R, Arria A, Haning W, Della Grotta S, Strauss A, Lester BM, Huestis MA. New meconium biomarkers of prenatal methamphetamine exposure increase identification of affected neonates. Clin Chem. 2010 May; 56(5):856-60.
Score: 0.004
-
Gray TR, LaGasse LL, Smith LM, Derauf C, Grant P, Shah R, Arria AM, Della Grotta SA, Strauss A, Haning WF, Lester BM, Huestis MA. Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant Development, Environment and Lifestyle (IDEAL) study. Ther Drug Monit. 2009 Dec; 31(6):769-75.
Score: 0.004
-
Gray TR, Kelly T, LaGasse LL, Smith LM, Derauf C, Haning W, Grant P, Shah R, Arria A, Strauss A, Lester BM, Huestis MA. Novel biomarkers of prenatal methamphetamine exposure in human meconium. Ther Drug Monit. 2009 Feb; 31(1):70-5.
Score: 0.004
-
Paz MS, Smith LM, LaGasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Liu J, Lester BM. Maternal depression and neurobehavior in newborns prenatally exposed to methamphetamine. Neurotoxicol Teratol. 2009 May-Jun; 31(3):177-82.
Score: 0.004
-
Smith LM, Lagasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Fallone M, Liu J, Lester BM. Prenatal methamphetamine use and neonatal neurobehavioral outcome. Neurotoxicol Teratol. 2008 Jan-Feb; 30(1):20-8.
Score: 0.004
-
Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV, Chiang N, Kahn R, Vocci F, Ling W, Pearce VJ, McCann M, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Weis D. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology. 2008 Apr; 33(5):1162-70.
Score: 0.004
-
Elkashef A, Rawson RA, Smith E, Pearce V, Flammino F, Campbell J, Donovick R, Gorodetzky C, Haning W, Mawhinney J, McCann M, Weis D, Williams L, Ling W, Vocci F. The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity. Addiction. 2007 Apr; 102 Suppl 1:107-13.
Score: 0.004
-
Derauf C, LaGasse LL, Smith LM, Grant P, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Liu J, Lester BM. Demographic and psychosocial characteristics of mothers using methamphetamine during pregnancy: preliminary results of the infant development, environment, and lifestyle study (IDEAL). Am J Drug Alcohol Abuse. 2007; 33(2):281-9.
Score: 0.004
-
Smith LM, LaGasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Liu J, Lester BM. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics. 2006 Sep; 118(3):1149-56.
Score: 0.004
-
Arria AM, Derauf C, Lagasse LL, Grant P, Shah R, Smith L, Haning W, Huestis M, Strauss A, Della Grotta S, Liu J, Lester B. Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study. Matern Child Health J. 2006 May; 10(3):293-302.
Score: 0.003